相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antiretroviral Resistance Patterns and Factors Associated With Resistance in Adult Patients Failing NNRTI-Based Regimens in the Western Cape, South Africa
Gert U. van Zyl et al.
JOURNAL OF MEDICAL VIROLOGY (2011)
Can We Treat Our Way Out of HIV?
Rowena Johnston et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2010)
HIV Type 1 Antiretroviral Resistance Mutations in Subtypes B, C, and F in the City of Sao Paulo, Brazil
Patricia Munerato et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2010)
International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase
Philip M. Grant et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Evolution of Drug Resistance During 48 Weeks of Zidovudine/Lamivudine/Tenofovir in the Absence of Real-Time Viral Load Monitoring
Fred Lyagoba et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Viral Rebound and Emergence of Drug Resistance in the Absence of Viral Load Testing: A Randomized Comparison between Zidovudine-Lamivudine plus Nevirapine and Zidovudine-Lamivudine plus Abacavir
Nicasie Ndembi et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy
Mina C. Hosseinipour et al.
AIDS (2009)
High Frequency of Clinically Significant Mutations after First-Line Generic Highly Active Antiretroviral Therapy Failure: Implications for Second-Line Options in Resource-Limited Settings
N. Kumarasamy et al.
CLINICAL INFECTIOUS DISEASES (2009)
Clinical and Genotypic Findings in HIV-Infected Patients With the K65R Mutation Failing First-Line Antiretroviral Therapy in Nigeria
Claudia A. Hawkins et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008)
Jorge L. Martinez-Cajas et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2009)
Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens
Florence Doualla-Bell et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2009)
Second-line antiretroviral therapy in resource-limited settings:: the experience of Medecins Sans Frontieres
Mar Pujades-Rodriguez et al.
AIDS (2008)
Tolerability and effectiveness of first-line regimens combining Nevirapine and lamivudine plus zidovudine or Stavudine in Cameroon
Christian Laurent et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2008)
Efficacy and tolerability of a double boosted protease inhibitor (lopinavir plus saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors
Ploenchan Chetchotisakd et al.
HIV MEDICINE (2007)
The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa
Vlad Novitsky et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2007)
Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails
Somnuek Sungkanuparph et al.
CLINICAL INFECTIOUS DISEASES (2007)
First molecular surveillance report of HIV type 1 in injecting drug users and female sex workers along the U.S.-Mexico border
L. Eyzaguirre et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2007)
In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine
N. A. Margot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level
Urvi M. Parikh et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Web resources for HIV type 1 genotypic-resistance test interpretation
TF Liu et al.
CLINICAL INFECTIOUS DISEASES (2006)
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)
A Castagna et al.
AIDS (2006)
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent
J Snoeck et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration
R Kantor et al.
PLOS MEDICINE (2005)
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients
MD Miller et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Resistance issues with new nucleoside/nucleotide backbone options
MA Wainberg et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviral-naive patients - A 3-year randomized trial
JE Gallant et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure
AG Marcelin et al.
JOURNAL OF MEDICAL VIROLOGY (2004)
Predictors of selection of K65R:: tenofovir use and lack of thymidine analogue mutations
L Valer et al.
AIDS (2004)
Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates
JM Whitcomb et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF
NA Margot et al.
AIDS (2002)
Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution
M Peeters et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2000)
分享论文
